PDS Biotechnology (PDSB) Scheduled to Post Quarterly Earnings on Wednesday

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) is set to announce its earnings results before the market opens on Wednesday, May 15th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.05. On average, analysts expect PDS Biotechnology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PDS Biotechnology Stock Up 6.5 %

Shares of PDSB stock traded up $0.24 on Wednesday, hitting $4.02. The company's stock had a trading volume of 1,836,841 shares, compared to its average volume of 849,016. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.33 and a quick ratio of 4.33. The stock has a market capitalization of $147.45 million, a price-to-earnings ratio of -2.91 and a beta of 1.75. PDS Biotechnology has a fifty-two week low of $2.59 and a fifty-two week high of $10.27. The firm's fifty day moving average price is $4.13 and its 200-day moving average price is $4.79.

Analyst Ratings Changes

PDSB has been the subject of several recent analyst reports. B. Riley reiterated a "buy" rating and set a $11.00 price target (down previously from $14.00) on shares of PDS Biotechnology in a research note on Thursday, March 28th. StockNews.com lowered shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday, March 16th. HC Wainwright restated a "buy" rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research note on Wednesday, March 27th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of PDS Biotechnology in a research note on Friday, January 12th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $17.33.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.